Form 4: Organon & Co. Director Robert Essner Reports Phantom Stock Acquisition

Robert Essner, a Director at Organon & Co., reported the acquisition of 17,857.143 phantom stock units on June 12, 2026, as part of the company's Non-Employee Director Savings Plan.

Summary

• Director Robert Essner acquired 17,857.143 phantom stock units on June 12, 2026.
• These phantom stock units are part of the Organon Non-Employee Director Savings Plan.
• The phantom stock units are economically equivalent to Organon common stock on a 1-for-1 basis.
• The units are payable in cash upon termination of service as a director.
• The acquisition price is noted as $13.44 per unit.
• Following this transaction, Essner beneficially owns 81,141.129 phantom stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of insider transactions and does not provide new information on the company's financial health or strategic direction.

Positives

• Director Essner's continued participation and investment in the company's equity incentive plan.
• The acquisition of phantom stock units indicates a commitment to the company's long-term performance.
• Dividend reinvestment in phantom stock, as noted for previous acquisitions, suggests a strategy of compounding returns for directors.

Negatives

• The filing only details a transaction for a director and does not provide broader company financial performance data.
• Phantom stock is a cash-settled award, meaning no actual shares are issued, which may limit direct shareholder alignment compared to stock options or grants.

Risks

• The value of the phantom stock is tied to the performance of Organon's common stock, thus subject to market volatility.
• Payment in cash upon termination of service means the director will not hold actual company stock post-service, potentially impacting long-term alignment.
• The plan's terms and conditions, including cash settlement, could be subject to change.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a change in beneficial ownership for a director.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of phantom stock units by Organon & Co. for its directors is a common practice in the pharmaceutical and healthcare sectors, aiming to align executive compensation with company performance without diluting existing shareholder equity through direct share issuance.

Related Party Transactions

• The acquisition of phantom stock units by Director Robert Essner is a related party transaction, as it involves a company insider.

Stakeholder Impact

• Shareholders: The transaction itself does not directly impact share count or immediate ownership structure, but reflects director compensation practices.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.

Next Steps

• Phantom stock units are payable in cash upon termination of service as a director.
• Future dividend reinvestment transactions may occur, as indicated by prior activity.

Key Dates

Keywords

Organon & Co., OGN, Form 4, Insider Trading, Director, Phantom Stock, Equity Incentive Plan, Beneficial Ownership, SEC Filing, Robert Essner